OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.66
+0.41 (+4.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.25
Open9.26
Bid0.00 x 1100
Ask0.00 x 800
Day's Range9.08 - 10.50
52 Week Range4.44 - 11.23
Volume406,196
Avg. Volume236,729
Market Cap400.69M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.60
  • GlobeNewswire

    Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects.

  • Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2019, after market close on Tuesday, November 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

    Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

    YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --  Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael Richardson into the new position. In this role, Michael will be responsible for identifying, evaluating, and executing on business development opportunities that support the overall corporate strategy.

  • GlobeNewswire

    Optinose to Present at the 2019 Cantor Global Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2019 Cantor Global Healthcare Conference on October 2, 2019, at 11:15 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

  • PR Newswire

    Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

    Currax's first acquisition comes fewer than five months after the company's founding in April of 2019 The acquisition of ONZETRA® Xsail® bolsters Currax's Branded products portfolio MORRISTOWN, N.J. , ...

  • GlobeNewswire

    OptiNose Announces License Agreement Related to ONZETRA XSAIL

    OptiNose, Inc. (Optinose) (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement between its Norway-based subsidiary OptiNose AS and Currax Pharmaceuticals LLC (Currax) which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico. Under the terms of the License Agreement, Currax is required to pay a $4.48 million upfront payment, of which $750,000 shall be held in escrow for a limited period to cover certain indemnification obligations.

  • GlobeNewswire

    Optinose Announces Departure of Chief Commercial Officer

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its Chief Commercial Officer, Tom Gibbs. Mr. Gibbs will be leaving the Company next week to assume a senior general management role at a major multinational pharmaceutical company. Senior members of the Optinose commercial leadership, including Vice Presidents of sales, marketing, and market access, will report directly to Optinose President and Chief Operating Officer Ramy Mahmoud on an interim basis as the Company initiates a search for a Chief Commercial Officer.

  • GlobeNewswire

    Optinose Announces $150 Million Debt Financing from Pharmakon

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes with funds managed by Pharmakon Advisors, LP (“Pharmakon”), the investment manager of the BioPharma Credit funds. “The capital available under this facility has the potential to meaningfully extend our cash runway, and Pharmakon’s reputation of forming successful, long-term, relationships with growth-stage companies such as Optinose makes them a great financial partner for us,” commented Chief Financial Officer Keith Goldan.

  • Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?
    Simply Wall St.

    Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Benzinga

    OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says

    OptiNose Inc’s (NASDAQ: OPTN ) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC Capital Markets. ...

  • OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript

    OPTN earnings call for the period ending June 30, 2019.

  • OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 12.00% and -13.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net.

  • ACCESSWIRE

    OptiNose, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / OptiNose, Inc. (NASDAQ: OPTN) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 PM Eastern ...

  • Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second quarter 2019, after market close on Monday, August 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It
    Simply Wall St.

    Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It

    OptiNose, Inc. (NASDAQ:OPTN) shareholders should be happy to see the share price up 14% in the last month. But that...

  • GlobeNewswire

    Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2019 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 25, 2019, at 9:40 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

  • GlobeNewswire

    Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2019 in the medium-sized company category. “From the very start of Optinose in 2010, we believed that hiring great people and creating a work environment in which those people can come together and accomplish even greater things together should be our highest priority,” said Peter Miller, CEO of Optinose. “Receiving public recognition of Optinose as a ‘Best Place to Work’ is an honor, and it is only possible because of the quality and commitment of our colleagues,” added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose.

  • InvestorPlace

    You Can Get Buy Signals From Short Selling

    You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.

  • OptiNose, Inc. (OPTN) Q1 2019 Earnings Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q1 2019 Earnings Call Transcript

    OPTN earnings call for the period ending March 31, 2019.

  • OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?